In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal P-glycoprotein by ritonavir causing increased darunavir absorption

Drug Metabolism and Disposition

Volumn 38, Issue 9, 2010, Pages 1407-1410

  Holmstock, Nico ^a   Mols, Raf ^a   Annaert, Pieter ^a   Augustijns, Patrick ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; ELACRIDAR; GLYCOPROTEIN P; RITONAVIR; VALSPODAR; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE FLUID; INTESTINE PERFUSION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIMULATION; WILD TYPE;

ANIMALS; CACO-2 CELLS; HIV PROTEASE INHIBITORS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS; RITONAVIR; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 77956008536     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032771     Document Type: Article

References (17)

1. Bevernage J, Brouwers J, Clarysse S, Vertzoni M, Tack J, Annaert P, and Augustijns P (2010) Drug supersaturation in simulated and human intestinal fluids representing different nutritional states. J Pharm Sci doi: 10.1002/jps.22154.
2. Brouwers J, Tack J, and Augustijns P (2007) In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation. Int J Pharm 336:302-309.
3. Busse KH and Penzak SR (2007) Darunavir: a second-generation protease inhibitor. Am J Health Syst Pharm 64:1593-1602.
4. Clarysse S, Tack J, Lammert F, Duchateau G, Reppas C, and Augustijns P (2009) Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states. J Pharm Sci 98:1177-1192.
5. Deferme S, Tack J, Lammert F, and Augustijns P (2003) P-Glycoprotein attenuating effect of human intestinal fluid. Pharm Res 20:900-903.
6. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, and Saito H (2009) P-Glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull 32:1588-1593.
7. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300:555-570.
8. Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, et al. (2008) Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 35:383-396.
9. Ho RH and Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260-277.
10. Kis O, Robillard K, Chan GN, and Bendayan R (2009) The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31: 22-35.
11. Lachau-Durand S, Annaert P, Steemans K, Willems B, Mannens G, Raoof A, and Meuldermans W (2006) Transport characteristics of the HIV protease inhibitor darunavir (TMC114) in Caco-2 monolayers. Proceedings of the Annual Meeting of the American Association of Pharmaceutical Sciences; 2006 Oct 29-Nov 2; San Antonio, TX. American Association of Pharmaceutical Sciences, Arlington, VA.
12. Lowry OH and Rosebrough NJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
13. Mols R, Brouwers J, Schinkel AH, Annaert P, and Augustijns P (2009) Intestinal perfusion with mesenteric blood sampling in wild-type and knockout mice: evaluation of a novel tool in biopharmaceutical drug profiling. Drug Metab Dispos 37:1334-1337.
14. Sekar V, Kestens D, Spinosa-Guzman S, De PauwM, De Paepe E, Vangeneugden T, Lefebvre E, and Hoetelmans RM (2007) The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 47:479-484.
15. Tremblay CL (2008) Combating HIV resistance - focus on darunavir. Ther Clin Risk Manag 4:759-766.
16. Van den Mooter G, Stas G, Damian F, Naesens L, Balzarini J, Kinget R, and Augustijns P (1998) Stability of UC-781, in intestinal mucosal homogenates of the rat, rabbit, and pig. Pharmacol Res 15:1799-1802.
17. Vertzoni M, Fotaki N, Kostewicz E, Stippler E, Leuner C, Nicolaides E, Dressman J, and Reppas C (2004) Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J Pharm Pharmacol 56:453-462.